Hersch et al. 2006: Creatine in Huntington's Disease — Phase II Clinical Trial

TL;DR — Hersch et al. 2006

Hersch and colleagues published a phase II clinical trial examining creatine supplementation in Huntington’s disease patients. The study, involving patients at multiple clinical sites, demonstrated that 8 g/day of creatine was safe and well tolerated over 16 weeks. Notably, brain creatine concentrations increased and a key marker of oxidative DNA damage decreased significantly. These findings supported the rationale for further investigation of creatine as a neuroprotective agent in Huntington’s disease.

Background

Huntington’s disease is a devastating hereditary neurodegenerative disorder caused by a mutation in the huntingtin gene. It leads to progressive motor, cognitive, and psychiatric decline. Mitochondrial dysfunction and impaired energy metabolism are central features of the disease pathology.

The phosphocreatine-creatine kinase system is critical for cellular energy buffering (T et al., 2011) . Preclinical research had shown that creatine could protect against neuronal damage in animal models of neurodegeneration (PG et al., 2000) . Hersch et al. designed this phase II trial to assess safety, tolerability, and biomarker effects before proceeding to larger efficacy trials.

Study Design

• Type: Phase II, randomized, double-blind, placebo-controlled trial
• Participants: Huntington’s disease patients with confirmed genetic diagnosis
• Dosing: 8 g/day creatine monohydrate or placebo
• Duration: 16 weeks
• Measurements: Brain creatine levels via MRS, serum 8-OH-2dG (oxidative damage marker), safety bloods, clinical assessments

Key Findings

1. Safety and tolerability confirmed

No serious adverse events were attributed to creatine supplementation. Gastrointestinal side effects were minimal and comparable between groups. Renal and hepatic function remained normal throughout the study.

2. Brain creatine increased

Magnetic resonance spectroscopy showed that brain creatine concentrations increased in the supplemented group, confirming that oral creatine can cross the blood-brain barrier and accumulate in neural tissue at therapeutic doses.

3. Oxidative stress marker decreased

Serum 8-hydroxy-2-deoxyguanosine (8-OH-2dG), a validated marker of oxidative DNA damage, decreased significantly in the creatine group. This suggests that creatine may reduce oxidative stress, which is a key pathological mechanism in Huntington’s disease.

Significance for Neurodegenerative Research

This trial was significant because it:

• Established a safe dosing protocol for creatine in a neurodegenerative disease population
• Provided biomarker evidence that creatine reaches the brain in clinically relevant concentrations
• Demonstrated a measurable reduction in oxidative stress with creatine supplementation
• Laid the groundwork for larger phase III trials

Practical Implications

1. Creatine can benefit the brain: The study confirmed that oral creatine increases brain creatine levels, supporting its potential as a neuroprotective agent
2. Higher doses may be needed for neural benefits: The 8 g/day dose used here is higher than the typical 3-5 g/day athletic dose, reflecting the challenge of blood-brain barrier transport
3. Safety extends to clinical populations: Creatine’s safety profile holds even in patients with serious neurological conditions
4. Oxidative stress reduction is a bonus: Beyond energy metabolism, creatine may help combat oxidative damage in the brain

Malaysian Relevance

While Huntington’s disease is relatively rare in Malaysia, the broader implications of this study are relevant. The confirmation that creatine can increase brain creatine levels and reduce oxidative stress applies to brain health generally, supporting the use of creatine as a neuroprotective supplement as endorsed by the ISSN (RB et al., 2017) .

Limitations

• Phase II trial not designed to measure clinical efficacy
• Relatively short duration of 16 weeks
• Small sample size typical of phase II trials
• Long-term effects at 8 g/day in this population remain unknown

Full Citation

Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology. 2006;66(2):250-252. doi:10.1212/01.wnl.0000194318.74946.b6

Study Design and Methodology

Understanding how a study was designed helps assess the strength of its conclusions. Key methodological factors to evaluate include:

• Sample size — larger studies (n=50+) provide more reliable results than small studies (n=10-15). Small sample sizes increase the risk of false positives and limit the ability to detect moderate effect sizes
• Study duration — creatine research requires adequate duration for muscle saturation (minimum 4 weeks for maintenance dosing, 1 week for loading). Studies shorter than this may miss the full effect
• Blinding — double-blind, placebo-controlled designs (where neither researchers nor participants know who receives creatine) are the gold standard for minimising bias
• Population studied — results from trained athletes may not fully apply to untrained individuals, and vice versa. Age, sex, and dietary habits (particularly vegetarian status) also influence creatine response
• Outcome measures — direct measures (muscle biopsy, MRS imaging) are more informative than indirect proxies (blood markers, performance tests) for assessing creatine uptake and metabolism

Clinical Implications and Practical Relevance

This research contributes to our understanding of creatine in several practical ways:

For athletes and fitness enthusiasts: The findings support the use of creatine monohydrate as a safe, effective ergogenic aid. The standard dosing protocol of 3-5g daily remains well-supported by the cumulative evidence base including this study.

For healthcare professionals: Understanding the specific mechanisms and safety data from studies like this helps clinicians provide evidence-based guidance to patients who ask about creatine supplementation. The research consistently shows a favourable safety profile at recommended doses.

For the Malaysian context: While most creatine research is conducted in Western populations, the fundamental biochemistry (ATP-phosphocreatine system) is universal. Malaysian consumers can apply these findings with confidence, adjusting for local factors like tropical climate (increased hydration needs) and halal dietary requirements (synthetic creatine monohydrate is permissible).

How This Fits Into the Broader Evidence

No single study should be used to make definitive claims about creatine supplementation. Instead, this research should be viewed as one piece of a much larger evidence base:

• The ISSN Position Stand (2017) synthesises hundreds of studies into comprehensive recommendations
• Multiple systematic reviews and meta-analyses confirm creatine’s effects on strength, power, and lean mass
• Long-term safety data spanning up to 5 years shows no adverse effects at recommended doses

For a complete overview of the evidence, explore our Research Library which covers 60+ landmark creatine studies.

Sources & References

This article is based on the phase II trial by Hersch et al. published in Neurology (2006) and contextualized with Wallimann et al. (2011) and Sullivan et al. (2000). All citations reference PubMed-indexed publications.

Further Reading

• creatine dosage guide
• creatine safety profile
• creatine monohydrate
• creatine for brain health
• how creatine works
• buying creatine in Malaysia